Compare Vanguard International High Dividend Yield ETF (VYMI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard International High Dividend Yield ETF vs GeneDx Holdings Corp — how do they compare? Vanguard International High Dividend Yield ETF trades at $100.53 (market cap $22.80B), while GeneDx Holdings Corp trades at $68.16 (market cap $2.02B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 11.3× GeneDx Holdings Corp's market cap, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard International High Dividend Yield ETF for 50 Days and GeneDx Holdings Corp for 19 Days on average.
| VYMI | WGS | |
|---|---|---|
Market Cap | $22.80B | $2.02B |
Volume | 748,441 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $107.13 | $167.51 |
52-Week Low | $82.92 | $34.51 |
Typical Hold Time | 50 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYMI trades at $100.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. Recent news highlights institutional accumulation and positive performance comparisons to peers. The ETF's international high-dividend strategy focuses on financials, energy, and healthcare sectors.
Outlook remains mixed: bullish sentiment from media and institutional inflows contrasts with bearish technicals. Key opportunities include sector alignment with rising rates and attractive yield; risks involve global economic volatility and concentrated financial exposure. Investors should weigh dividend stability against technical weakness.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
